Thus, there are likely to be other proteins in SMA skeletal muscle yet to be identified that have the potential to act as novel biomarkers for the disease alongside GRP75/Mortalin and Calreticulin. This evidence concerns the gene HSPA9 and proximal spinal muscular atrophy.